Recombinant Human TRAIL/TNFSF10 Protein, CF 375-TL-010/CF from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human TRAIL/TNFSF10 Protein, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $454.00Supplier Page View Company Product Page
Catalog Number375-TL-010/CF
SpeciesHuman
Size10 ug
FormatLyophilized from a 0.2 µm filtered solution in PBS
Molecule NameTRAIL/TNFSF10
NCBI Full Gene NameTNF superfamily member 10
NCBI Gene AliasesTNLG6A, TL2, CD253, TANCR, TRAIL, Apo-2L, APO2L
Purity>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Molecular WeightObserved: 24 kDa, reducing conditions
Theoretical: 21 kDa (monomer)
ApplicationsBioactivity
Conjugate/TagUnconjugated
Source/Expression SystemNS0-derived Recombinant Human TRAIL/TNFSF10 Protein, CF
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -70 °C under sterile conditions after reconstitution

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(3) CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicityNature communicationsMarch 25, 2022Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, Macrae RK, Deasy R, Tseng YY, Maus MV, et al.

(4) Targeting hypoxia-induced tumor stemness by activating pathogen-induced stem cell niche defenseFrontiers in immunologyJanuary 1, 2022Bhuyan S, Pal B, Pathak L, Saikia PJ, Mitra S, Gayan S, Mokhtari RB, Li H, Ramana CV, Baishya D, et al.

(5) Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199Molecular cancer therapeuticsDecember 1, 2021Wang BT, Kothambawala T, Wang L, Matthew TJ, Calhoun SE, Saini AK, Kotturi MF, Hernandez G, Humke EW, Peterson MS, et al.incubated at 37°C overnight, then treated with IGM-8444 or recombinant human TRAIL ligand (R&D Systems #375-TL-010/CF) for 24 hours. For combination studies, IGM-8444 and chemotherapeutic agents or ABT-199 were incubated

(7) The Obesity-Susceptibility Gene TMEM18 Promotes Adipogenesis through Activation of PPARGCell reportsOctober 20, 2020Landgraf K, Klöting N, Gericke M, Maixner N, Guiu-Jurado E, Scholz M, Witte AV, Beyer F, Schwartze JT, Lacher M, et al.

(8) TRAIL inhibits oxidative stress in human aortic endothelial cells exposed to pro-inflammatory stimuliPhysiological reportsOctober 1, 2020Forde H, Harper E, Rochfort KD, Wallace RG, Davenport C, Smith D, Cummins PM.

(10) The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1The Journal of biological chemistryDecember 6, 2019O'Hara SP, Splinter PL, Trussoni CE, Guicciardi ME, Splinter NP, Al Suraih MS, Nasser-Ghodsi N, Stollenwerk D, Gores GJ, LaRusso NF.

(13) MiR-1208 Increases the Sensitivity to Cisplatin by Targeting TBCK in Renal Cancer CellsInternational journal of molecular sciencesJuly 19, 2019Kim EA, Jang JH, Sung EG, Song IH, Kim JY, Lee TJ.

(16) RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancerOncogeneMay 1, 2019Kim BR, Park SH, Jeong YA, Na YJ, Kim JL, Jo MJ, Jeong S, Yun HK, Oh SC, Lee DH.

(17) Activated NK cells kill hepatic stellate cells via p38/PI3K signaling in a TRAIL-involved degranulation mannerJournal of leukocyte biologyApril 1, 2019Li T, Yang Y, Song H, Li H, Cui A, Liu Y, Su L, Crispe IN, Tu Z.

(18) Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition diseaseOsteoarthritis and cartilageJune 1, 2018Williams CJ, Qazi U, Bernstein M, Charniak A, Gohr C, Mitton-Fitzgerald E, Ortiz A, Cardinal L, Kaell AT, Rosenthal AK.

(19) An anti-TL1A antibody for the treatment of asthma and inflammatory bowel diseasemAbsMay 1, 2018Clarke AW, Poulton L, Shim D, Mabon D, Butt D, Pollard M, Pande V, Husten J, Lyons J, Tian C, et al.

(20) Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal CancerMolecular cancer research : MCRMarch 1, 2018Zhang P, Kawakami H, Liu W, Zeng X, Strebhardt K, Tao K, Huang S, Sinicrope FA.

Recombinant Human TRAIL/TNFSF10 Protein, CF from R&D Systems, a Bio-Techne Brand